id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-011030-o4jn5883	Hakki, Morgan	Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy	2020-01-24		.txt	text/plain	7454	384	39	A subset of patients were categorized as CMV high-risk, including HLA-A, B, or DR mismatch related donor, HLA-A, B, C, and DRB1 mismatch unrelated Excludes overlapping toxicities with agents commonly used after HCT 3 Approved by the US FDA (year of approval) for prevention and/or treatment 4 ND, not determined donor, haploidentical donor, cord blood transplant, ex vivo T cell-depleted graft, or graft-versus-host disease (GVHD) of grade 2 or greater requiring ≥ 1 mg/kg/day prednisone (or equivalent). A subsequent phase 3 study evaluated maribavir at 100 mg twice daily compared with placebo for the prevention of CMV infection and disease in allogeneic HCT recipients [64] . Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem-cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, doseranging study	./cache/cord-011030-o4jn5883.txt	./txt/cord-011030-o4jn5883.txt